BC
Binita Chakraborty
Duke University, University of Nebraska Medical Center, University of Calcutta
Employment
-
Duke University Post Doctoral Associate2016 - Present
Education
-
University of Nebraska Medical Center Graduate Student2009 - 2015
-
University of Calcutta B.Sc2002 - 2005
Projects & Funding
Projects & funding information is unavailable.
Publications (58)
- Supplementary Figure S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models Save
- Data from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy Save
- The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models Save
- Supplementary Table S6 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models Save
- Supplementary Table S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models Save
- Supplementary Table S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models Save
- Supplementary Table S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models Save
- Supplementary Table S2 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models Save
- Supplementary Table S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models Save
- Supplementary Figure S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models Save